DNA-Dependent Protein Kinase Is a Therapeutic Target and an Indicator of Poor Prognosis in B-Cell Chronic Lymphocytic LeukemiaElaine Willmore(Newcastle University), Barbara W. DurkaczClinical Cancer ResearchJune 15, 200810.1158/1078-0432.ccr-07-5158Cited by 91SaveCiteExport RISWatch citationsRelated PapersRadiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1.|PubMed|2003|331PARP1 expression, activity and<i>ex vivo</i>sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia|Oncotarget|2015|30Expression and Activity of the NF-κB Subunits in Chronic Lymphocytic Leukaemia: A Role for RelB and Non-Canonical Signalling|Cancers|2023|4